ET二周与三周方案在局部进展期乳腺癌新辅助治疗中应用的对比观察  

Clinical comparative observation of neoadjuvant chemotherapy with ET every two weeks and ET every three weeks regimens for the treatment of locally advanced breast cancer

作　　者：阚士锋[1] 贾锋[2] 

机构地区：[1]山东枣庄市立医院肿瘤科,277102 [2]山东济宁医学院附属金乡医院肿瘤内科,272200

出　　处：《中国肿瘤临床与康复》2008年第3期266-268,271,共4页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的观察对比表阿霉素联合泰索帝(ET)二周与三周化疗方案术前治疗局部进展期乳腺癌(LABC)的有效率(CR+PR)、病理完全缓解(原发灶和腋窝淋巴结无浸润癌残留,pCR)率、保乳率、术前等候时间以及毒副反应。方法共有90例患者入组,随机分为ET二周组(48例)和ET三周组(42例)。ET二周组治疗方案为:表阿霉素40mg/m2,ivdrip,d1,2;泰索帝60mg/m2,ivdrip1h,d3;2周为1周期,共化疗3周期。ET三周组方案用药不变,以3周做为1周期,共化疗3周期。完成3周期新辅助治疗后10～14d行手术或改其他治疗方案。结果ET二周组(48例)病理完全缓解6例(12.5%),总有效率89.6%,行保乳手术14例(29.2%),术前中位等候时间53d;ET三周组(42例)病理完全缓解3例(7.1%),总有效率69.1%,行保乳手术5例(11.9%),术前中位等候时间76d。治疗过程中两组均有程度不等的骨髓抑制、胃肠道反应等毒副反应。两组无一例患者终止治疗,均未发生药物所致的死亡。结论ET二周密集化疗方案术前治疗局部进展期乳腺癌疗效优于三周常规方案,缩短了术前等待时间,且耐受性好。Objective To compare the efficacy and toxicity of ET [ taxotere （TXT） combined with epirubicin（EPI） ] every two weeks and ET every three weeks regimens in the neoadjuvant chemotherapy of locally advanced breast cancer（LABC）. Methods Ninety cases with LABC were randomly divided into two groups. The patients in group ET every two weeks （ N = 48） received the following regimen ： EP140 mg/m^2, iv gtt d1,2; TXT：60 mg/m^2, iv gtt 1 h,d3 ,repeated every two weeks ; the patients in group ET every three weeks （ N = 42 ） received the same medicament, but repeated every three weeks. Three cycles were one course of treatment. Results The total response rate （ CR ＋ PR） and pCR of the ET every two weeks group were 89.6% and 12.5%, those of another group were 69.1% and 7.1% respectively. The main toxicity of these two regimens was bone marrow suppression and gastroenteric side effect. Conclusion The two weeks regiman of taxotere combined with epirubicin is well tolerated and effective in the neoadjuvant chemotherapy of locally advanced breast cancer.

关 键 词：乳腺肿瘤/化学疗法 泰索帝 表阿霉素 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]